Athira Pharma Inc (ATHA)

$0.53 0.00 (-0.17%)
Market Cap 20.53M
Revenue (ttm) 0.00
Net Income (ttm) -117.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 44,500
Avg Vol 761,046
Day's Range N/A - N/A
Shares Out 38.67M
Stochastic %K 12%
Beta 2.99
Analysts Hold
Price Target $7.70

Latest News on ATHA

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Jan 7, 2025, 5:15 PM EST - 10 days ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Dec 6, 2024, 5:30 PM EST - 6 weeks ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Nov 7, 2024, 4:05 PM EST - 2 months ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 11:59 AM EDT - 4 months ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 17, 2024, 9:00 AM EDT - 4 months ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 4, 2024, 8:48 AM EDT - 4 months ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:13 PM EDT - 4 months ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Sep 3, 2024, 4:01 PM EDT - 4 months ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Aug 1, 2024, 4:05 PM EDT - 6 months ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jul 31, 2024, 8:05 AM EDT - 6 months ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Jun 12, 2024, 7:00 AM EDT - 7 months ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma to Participate in Upcoming June Conferences

May 29, 2024, 7:00 AM EDT - 8 months ago

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 17, 2024, 5:00 PM EDT - 8 months ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 15, 2024, 4:05 PM EDT - 8 months ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma to Participate in Upcoming May Conferences

May 2, 2024, 7:00 AM EDT - 9 months ago

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 15, 2024, 7:00 AM EDT - 9 months ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 11, 2024, 7:00 AM EDT - 10 months ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 3, 2024, 7:00 AM EDT - 10 months ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Mar 8, 2024, 7:00 AM EST - 11 months ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 22, 2024, 4:05 PM EST - 11 months ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Feb 8, 2024, 4:02 PM EST - 1 year ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 8, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Jan 3, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Dec 12, 2023, 7:00 AM EST - 1 year ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 29, 2023, 7:00 AM EST - 1 year ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 15, 2023, 8:15 AM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Athira Pharma to Participate in Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 1 year ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Oct 5, 2023, 4:30 PM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 17, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Jul 6, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 22, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

Athira Pharma to Participate in Upcoming May Investor Conferences

May 8, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 25, 2023, 4:01 PM EDT - 1 year ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 28, 2023, 1:00 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 23, 2023, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Mar 6, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Feb 1, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 31, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Athira Pharma Provides 2023 Pipeline Outlook

Jan 5, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2023 Pipeline Outlook

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Dec 21, 2022, 7:00 AM EST - 2 years ago

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Dec 5, 2022, 7:30 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

Nov 29, 2022, 11:00 AM EST - 2 years ago

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Nov 28, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 21, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

Nov 10, 2022, 4:05 PM EST - 2 years ago

Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

Athira Pharma to Present at Stifel 2022 Healthcare Conference

Nov 9, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present at Stifel 2022 Healthcare Conference

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

Nov 7, 2022, 7:00 AM EST - 2 years ago

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference